Company profile
Vaccine Research & Development, Molecular Diagnostics | iQur
iQur is at the forefront of vaccine research and development and molecular diagnostics
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
AA | Transaction MzUyNjE4NDI2OGFkaXF6a2N4
Published 10 Jun 2026 09:52
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Sep 2013 to 31 Aug 2014
Malaria remains a major cause of death, particularly in many developing countries. Currently no vaccine is commercially available and existing pharmaceuticals are becoming less and less effective due to parasitic resistance, while insecticide resistance in diminishing the utility of that intervention. Therefore, we propose to develop an new and potent vac...
1 Nov 2009 to 31 Jul 2012
This project is a further development of the tandem core® vaccine platform which is likely to have a wide utility in the generation of powerful new vaccines. This platform has a number of advantages including high immunogenicity, good stability and decreased cost of goods due to the fact that only a single protein is made. Previously, we had shown that ta...
1 Sep 2007 to 30 Nov 2009
Awaiting Public Summary
